GO
Loading...

Enter multiple symbols separated by commas

Stocks Biogen Inc

More

  • Biogen takes on Alzheimer's Tuesday, 28 Apr 2015 | 4:29 PM ET
    alzheimer's

    George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.

  • Biotechs stick it to stocks Monday, 27 Apr 2015 | 4:30 PM ET
    Medical injection

    Biotech is getting roughed up, after leading the market's gains this year.

  • What's wrong with healthcare and biotech? Monday, 27 Apr 2015 | 3:32 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.

  • April 24- Slowing sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief...

  • April 24- Sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera fell on a sequential basis in the first quarter for the first time since its launch in 2013, sending the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued...

  • Wall Street eyes data, Greece meeting Friday, 24 Apr 2015 | 9:05 AM ET
    An image of Mark Zuckerberg, chief executive officer of Facebook Inc., left, with Robert Greifeld, chief executive officer of Nasdaq OMX Group, right, is projected at the Nasdaq MarketSite in New York, May 18, 2012.

    U.S. stock index futures indicated a higher open on Friday, as investors cheered a record Nasdaq close spurred by positive earnings.

  • Early movers: BIIB, XRX, MSFT, AMZN, SBUX & more Friday, 24 Apr 2015 | 8:09 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Tecfidera raked in sales of $824.9 million in the first quarter ended March 31, compared with $506 million a year earlier, but missed consensus projections of about $931 million, according to Deutsche Bank. We saw moderating patient growth of Tecfidera in the United States and Germany, Chief Executive George Scangos said in a statement. Net income attributable...

  • April 24- Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis drug, Tecfidera. The U.S. biotechnology company's net profit soared to $822.5 million, or $3.49 per share, in the first quarter ended March 31, from $480 million, or $2.02 per share, a year earlier. Excluding items, Biogen earned...

  • Wall Street looks to finish week strong Friday, 24 Apr 2015 | 6:10 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Big tech names will dominate market movements on Friday, with continuation of Greece debt talks and just one economic data point expected.

  • Traders focus on tech, but keep one eye on Greece Thursday, 23 Apr 2015 | 6:42 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Big tech names will dominate market movements on Friday, with continuation of Greece debt talks and just one economic data point expected.

  • Four trades to go before the closing bell Thursday, 23 Apr 2015 | 2:53 PM ET

    The "Halftime Report" traders give their top trades for the second half of the trading day.

  • Bang for your buck: Where earnings surprises are Thursday, 23 Apr 2015 | 8:28 AM ET
    Traders on the floor of the New York Stock Exchange.

    Three sectors are seeing the biggest rallies following earnings reports. Where investors should place future bets.

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • Tuesday's after-hours buzz: CSX, Intel & more Tuesday, 14 Apr 2015 | 4:59 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Take a look at some of Tuesday's after-hours buzz: Intel, Biogen & more

  • Why do drugs have such weird names? Friday, 10 Apr 2015 | 7:00 AM ET
    Pharmacist dispensing pills

    It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.

  • 5 biotech bets: Trading a surging sector Thursday, 9 Apr 2015 | 7:36 PM ET
    Amgen

    CNBC "Fast Money" traders discussed how to trade big names in the surging but uncertain biotechnology sector.